

Monosialoganglioside GM₁ Shortens the Blood Circulation Time of Liposomes in Rats

Dexi Liu,^{1,2} Feng Liu,¹ and Young K. Song¹

Received May 12, 1994; accepted November 3, 1994

Inclusion of monosialoganglioside GM₁ into liposomes significantly enhances the circulation time of liposomes in mice. Conversely, intravenously injected GM₁-containing liposomes were rapidly removed from the blood circulation and accumulated in the liver and spleen in rats. In rats, increasing the GM₁ content in liposomes resulted in more rapid clearance from the blood. Increasing the membrane rigidity of liposomes further increased the liver uptake of GM₁-containing liposomes. The activity of GM₁ in enhancing the liposome uptake by rat liver appears to be mediated by complement components.

KEY WORDS: drug delivery; ganglioside GM₁; liposomes; opsonin; reticuloendothelial system; complement system.

INTRODUCTION

Liposomes, being colloidal particles, are cleared from the circulation by the macrophages of the reticuloendothelial system (RES), mainly in the liver and spleen (1). Although this natural homing activity of liposomes has provided opportunities to deliver drugs to the RES, it has been an obstacle for the delivery of drugs to other cells (2). Attempts to reduce the affinity of liposomes to the cells of the RES and hence prolong their circulation time in blood has been one of the focuses of the liposome research in the last decade. Recently, liposomes that show prolonged circulation times in blood have been developed (3–9). The major characteristic of these long-circulating liposomes is the inclusion of ganglioside GM₁ (5,6), hydrogenated phosphatidylinositol (HPI) (6), or polyethyleneglycol conjugated to phosphatidylethanolamine (PEG-PE) (7–9) as part of the liposome composition.

Even though the elevated tumor accumulation and therapeutic advantages of such long circulating liposomes in cancer therapy have been demonstrated (4,6,10), the mechanism(s) leading to such prolonged circulatory half-life has not been fully elucidated. Earlier studies with cultured macrophages demonstrated the importance of serum opsonins such as complements, immunoglobulins and fibronectin in enhancing liposome uptake by macrophages (11–13). Results of recent studies showed that the blood half-lives of liposomes are inversely proportional to the total amount of blood proteins bound to these liposomes (14). In this respect, coating of liposomes with GM₁, PEG-PE or HPI may reduce the binding of serum components to liposome surface, resulting in a decreased liposome affinity for the RES and

therefore prolonged circulation time. Alternatively, evidence has also been obtained suggesting that removal of liposomes from the blood is determined by the surface properties of liposomes. Liposomes of different lipid compositions and surface properties exhibit different affinities for interaction with the RES which then affects their circulation time in the blood (15). The reduced rate of liposome clearance by inclusion of GM₁, HPI or PEG-PE into the liposome bilayer may result from reduction of direct liposome affinity to the RES due to sterical stabilization of the liposomes (4). Furthermore, it has also been suggested that some particles such as liposomes and pathogenic microorganisms can attract suppressive substances called dysopsonins from the blood and thereby minimize their interaction with phagocytes (16,17). Thus, the prolonged circulation half-lives of liposomes may also be related to the binding of dysopsonins onto their surface.

In this report, we present the evidence that the function of GM₁ in prolonging liposome circulation time is animal species dependent. In mice, inclusion of GM₁ into liposomes decreases liposome affinity for the RES and results in a prolonged half-life in the blood. However, liposomes containing the same glycolipid showed reduced half-life in the blood and increased liver uptake in rats. We also demonstrate that in rats GM₁ in liposomes serves as a signal for RES clearance. The higher the GM₁ concentration in liposomes, the less time they stay in the blood. Employing liver perfusion techniques, we demonstrate that the accelerated removal of GM₁-containing liposomes from the blood of rats is likely mediated by serum components.

MATERIALS AND METHODS

Materials

Egg phosphatidylcholine (PC), distearoylphosphatidylcholine (DSPC), bovine brain phosphatidylserine (PS) were purchased from Avanti Polar Lipids. Ganglioside GM₁ was from Supelco and cholesterol (Chol) was from Sigma. ¹¹¹In-diethylenetriamine pentaacetic acid distearylamine complex (¹¹¹In-DTPA-SA) was prepared as described previously (10). Animals used were from Harlan Sprague Dawley, Inc.

Liposome Preparation

Liposomes composed of PC/Chol/X (X represents the third lipid component) with a mole ratio of 10:5:1 were prepared by extrusion (10). Briefly, lipids with a trace amount of ¹¹¹In-DTPA-SA as lipid marker were dried under N₂ gas and vacuum desiccated for at least 30 min. The lipid film was hydrated in PBS (pH 8.0) overnight at room temperature. DSPC-based liposomes were hydrated at 65°C, 10°C above the T_m of DSPC. The lipid suspension was then extruded 20 times through two layers of polycarbonate filters (Nucleopore) with pore size of 100 nm using a LiposoFast extruder (Avestin Inc.). The average diameter of liposomes measured by a submicron particle analyzer (Colter N4SD) was 120 ± 25 nm.

Biodistribution Studies

Liposomes were injected via the tail vein into either

¹ Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania 15261.

² To whom correspondence should be addressed.

mice (NIHS-3, male, 25–30 g) or rats (Sprague Dawley, male 300–350 g) anesthetized by ether at a dose of 5 μ mole lipid/Kg in a volume of 100 μ l for mouse or 200 μ l for rat. At different time intervals after liposome injection, approximately 50 μ l (mouse) or 200 μ l (rat) blood samples were collected via the tail vein. The exact volume of blood in each sample was determined by weighing. The blood concentration of liposomes at the various time intervals was calculated based on the assumption that amount of blood is 7.4% of body weight for mice (18) and 5.4% for rats (19).

Liposome distribution in different organs was analysed 4 hour after administration. Mice were bled via the retro orbital sinus and killed by cervical dislocation. Blood and other organs were collected and weighed, and the radioactivity in each organ was counted in a gamma counter. Blood contamination into each organ was corrected by using correction factors as described previously (10). Liposome distribution studies in different organs for rats were performed in the same way, except that blood was collected via the portal vein to insure maximum removal.

Single-Pass Perfusion Studies of Liposome Uptake by Liver

GM₁-containing liposomes (1 μ mole lipids) were incubated with either saline or 33% freshly collected serum in saline for 10 min at 37°C. The mixture was then perfused into the liver of an anesthetized rat via the portal vein at a rate of 7 ml per min. The inferior vena cava was cut at the beginning of the perfusion to drain the perfusion solution. The perfused liver was then washed with 20 ml of saline at the same perfusion rate. The amount of liposomes taken up by the liver was measured by counting the radioactivity in the liver.

RESULTS AND DISCUSSION

Comparison of Time-Dependent Clearance of GM₁-Containing Liposomes in Mice and Rats

In this study, the blood concentration of GM₁-containing liposomes as function of time was examined in mice and rats. Liposomes composed of PC/Chol/GM₁ (10:5:1, molar ratio) from a single batch were intravenously injected into animals at a dose of 5 μ mole lipid/Kg. Blood samples from each animal were collected via the tail vein at 5, 15, 30, 60 and 120 min. As shown in Figure 1, the clearance rates of liposomes from the same batch were very different in mice and rats. The blood clearance of liposomes in mice was log-linear with a $t_{1/2}$ of approximate 6 hours while the elimination of liposomes from the blood of rats was much faster and showed non-linear, biphasic pharmacokinetics. Biphasic clearance kinetics is typical for conventional liposomes in the mice (20), indicating the involvement of two different elimination mechanisms. The effect of GM₁ in prolonging the circulation time of liposomes is not seen in rats. For example, at 2 hour, over 80% of the injected dose was found in the blood of mice compared to less than 2% in rats. Such rapid clearance of liposomes in rats is not function of anesthetization or the weight of the animals. Unanesthetized animals, with body weight ranging from 200 to 400 g gave similar results (data not shown).




Fig. 1. Blood clearance of liposomes composed of PC/Chol/GM₁ (10:5:1, molar ratio) in mice (●) and rats (○). ¹¹¹In-labeled liposomes were injected intravenously at a dose of 5 μ mole lipid/Kg. Blood samples were collected from animals at different intervals and the total amount of liposomes in the blood was calculated based on counting the radioactivity of each sample. Data are presented as mean \pm S.D. ($n = 3$).

Organ Distribution of GM₁-Containing Liposomes

To determine the organ distribution of GM₁-containing liposomes in mice and rats, animals were sacrificed 4 hour after liposome injection, and the amount of liposomes in different organs were subsequently analyzed. About 60% of the injected liposomes was recovered from the blood of mice compared to less than 1% from the blood of rats (Fig. 2). In rats, liposomes accumulated mainly in the liver (60%) and spleen (22%) while other organs, including kidney, lung and heart showed minimum accumulation.

The species difference in the effects of GM₁ on liposome




Fig. 2. Tissue distribution of PC/Chol/GM₁ (10:5:1) liposomes in mice (■) and rats (□) 4 hour after i.v. injection. Data were presented as mean \pm S.D. of 3 animals for each species.

circulation time observed (Figs. 1 and 2) have led us to examine whether other lipid components would exhibit similar variations in mice and rats. Among the many lipids that have been investigated in the past, GM₁, PEG-PE, and PS were shown to have the most dramatic influence on liposome circulation time. In mice, both PEG-PE and GM₁, decrease the RES uptake of liposomes and increase the liposome half-life (3–9). In contrast, PS increases the RES uptake of liposomes and therefore decreases circulation time in blood (10,21). Since the activity of PEG-PE in prolonging the circulation time of liposomes in both rats and mice has been reported (for review, see ref. 3), we only tested the biodistribution of PS-containing liposomes in rats. As shown in Table 1, the corresponding activity of PS in regulating the biodistribution of liposomes in rats is the same as that in mice (10,21). PS-containing liposomes were rapidly cleared from the blood and accumulated in the liver and spleen. Over 80% of injected dose was found in liver and spleen at 4 hour while about 1% injected dose was found in the blood. The level of liposome accumulation in the RES for PS-containing liposomes is almost identical to that of GM₁-containing liposomes (84% in RES, 1% in blood). Therefore, GM₁ functions more like PS than PEG-PE in regulating the liposome circulation in rats.

To test whether the membrane rigidity of the GM₁-containing liposomes plays a role in determining the circulation time of liposomes in rats, we used DSPC as the matrix lipid for liposome preparation. Substitution of egg PC by DSPC enhanced liver uptake of GM₁-containing liposomes (Table 1). A more than 5-fold increase in RES/blood ratio was observed when DSPC instead of egg PC was used as the matrix lipid.

Effect of GM₁ Concentration in Liposomes on Liposome Blood Clearance

As shown in Table 1, GM₁ functions more like PS than PEG-PE in regulating liposome distribution in rats, i.e., GM₁

Table 1. Biodistribution of Liposomes in Rats Four-Hour Post Injection

Liposome Composition (molar ratio)	% Injected Dose ^a			
	Blood	Liver	Spleen	RES/Blood
PC/Chol/GM ₁				
10:5:0	42.1 ± 0.6	21.2 ± 3.8	5.8 ± 0.5	0.6
10:5:0.15	2.9 ± 0.4	47.7 ± 5.4	26.4 ± 4.2	25.5
10:5:1 ^b	1.0 ± 0.5	58.2 ± 3.1	26.8 ± 9.9	85.0
10:5:1.67	0.4 ± 0.1	71.3 ± 8.2	16.5 ± 5.2	219.5
DSPC/Chol/GM ₁				
10:5:1	0.2 ± 0.0	70.0 ± 2.0	23.4 ± 0.9	467.0
PC/Chol/PS				
10:5:1	1.2 ± 1.3	73.1 ± 3.0	12.1 ± 2.4	71.0

^a Data are given for blood, liver, and spleen which account for most of the dose injected. For other organs such as lung, heart, and kidney, % dose were below 1% and did not vary significantly among the liposome formulations tested. %injected dose in RES was calculated as the sum of liver and spleen. Data are presented as mean ± S.D. (n = 3–6).

^b Data taken from Figure 2.

accelerates the removal of liposomes from the blood of rats. To confirm this conclusion, we examined the effect of GM₁ concentration in liposome membranes on blood clearance. Figure 3 is a semi-log plot of liposome concentration in blood as a function of time. An approximate 8-fold reduction of liposome concentration in the blood was seen at the 2 hour time point when only 1% GM₁ was included in the lipid mixture. The more GM₁ included in the liposomes, the faster they were cleared from the blood. For instance, 4 hour after administration, over an 100-fold decrease in the blood concentration was observed with liposomes containing 10% GM₁ as compared to liposomes without GM₁ (Table 1). The RES to blood ratios also increased with increasing amounts of GM₁ in the liposomes. The RES/blood ratio for liposomes containing 10% GM₁ was more than 300-fold greater than that of the liposomes without GM₁.

Single-Pass Perfusion Studies of Liposome Uptake by Rat Liver

Two possibilities can account for the action of GM₁ in rats. First, macrophages in liver and spleen of the rats may have a higher affinity for GM₁ and therefore liposomes are captured by the RES much easier when GM₁ is part of liposome composition, resulting in their rapid removal from the blood. Second, liposome uptake by the RES may be mediated by serum opsonin(s). To test these two possibilities, we have employed the single-pass liver perfusion system. Liposomes containing 6.25% GM₁ were incubated in saline with or without 33% serum in a volume of 20 ml for 10 min at 37°C. The mixture was then perfused through the portal vein into liver. Just before the start of perfusion the blood circulation was broken at the inferior vena cava to release the blood and later the perfusion solution from the liver. Liposomes were allowed to pass through the liver only once in




Fig. 3. Effect of GM₁ concentration in liposomes on blood clearance of liposomes in rats. ¹¹¹In-labeled liposomes containing the indicated amount of GM₁ were intravenously injected. The molar ratio of PC to Chol was kept at 10:5 for all liposome preparations. Blood samples were collected and analyzed as described in the method section. (○) PC/Chol without GM₁, (▲) with 1% GM₁, (●) with 6.25% GM₁, and (■) with 10% GM₁. Data are presented as mean ± S.D. (n = 3).

order to minimize potential damage to the liver during perfusion. As shown in Table 2, less than 5% of liposomes were found in the liver when liposomes were incubated with saline. However, 10% of liposomes were found in the liver after single passage when they were preincubated with rat serum. No increase in uptake was observed with liposomes preincubated with mouse serum. Rat serum did not show any effect on the total liposome uptake by the perfused liver for liposomes without GM₁ (Table 2). Heat treatment (56°C for 30 min) of rat serum to inactivate the complement system abolished the serum activity for GM₁-containing liposomes.

The results presented above clearly show that the activity of GM₁ in regulating liposome affinity for the RES and therefore blood circulation time is different in mice and in rats. GM₁ decreases liposome affinity for the RES and increases liposome circulation in mice, whereas this same glycolipid enhances the RES uptake and therefore decreases the circulation time of liposomes in rats. The differences in liposome uptake by the RES between mice and rats seems specific to GM₁ since the influence of both PS and PEG-PE on liposome circulation time are the same in both species (Table 1) (3,10,21).

While the evidence that GM₁ has opposite effect on liposome circulation time in mice and rats is clear, the explanation for the difference remains speculative. Elimination of serum activity by heat treatment (Table 2) suggests the involvement of complement components. This conclusion agrees well with the earlier reports that liposomes are recognized by complement components via the classical or alternative pathways, depending on the liposome composition (22–25). It is possible that GM₁-containing liposomes become coated with complement components when they are injected into rats and then are removed from the blood by the RES through complement receptors. Lack of activity in mouse serum (Table 2) would indicate that the complement system in mouse is not sensitive to GM₁. An alternative explanation is involvement of anti-GM₁ antibodies which exist in rats but not in mice. In this case, GM₁-containing liposomes are bound by anti-GM₁ antibodies in the blood and complement system will be subsequently activated. Liposome-bound complement components such as C3 may lead

to the recognition of liposomes by the C3 receptors of the RES causing a rapid removal from the blood. These possibilities are currently under investigation in our laboratory and the results of these experiments will be presented in a separate report.

While the present data clearly show the important role of serum factors in mediating the pharmacokinetic differences of GM₁-liposomes in rats and mice, it is evident that macrophages of the RES in rats may have a higher affinity for GM₁-containing liposomes than those in mice. As is shown in Table 2, liposomes without GM₁ only showed about 2% liver uptake independent of the presence of serum. This uptake represents only about half the amount of GM₁-containing liposomes taken up by perfused liver in the absence of serum. Therefore, the accelerated removal of liposomes containing-GM₁ from the blood of rats may involve serum factors in addition to the high affinity of liposomes for the RES.

It is premature to propose a definite mechanism for the activity of GM₁ described in this report. However, the results presented here support the conclusion that, in addition to various parameters in the liposome preparation, the long-circulating property of a given liposome composition in the blood may depend on the animal species. From the practical point of view, it will be important to examine the liposome circulation half life in a given animal species if the long circulating properties of liposomes are to be used.

ACKNOWLEDGMENTS

Drs. Joseph Knapp and Adedayo Adedoyin assisted in proof-reading this manuscript. We would also like to thank Dr. Leaf Huang for his generous help in providing us with some of the reagents and unlimited excess to the equipment in his laboratory. This work is supported by a starting fund from the University of Pittsburgh.

REFERENCES

1. R. L. Juliano. Factors affecting the clearance kinetics and tissue distribution of liposomes, microspheres and emulsions. *Adv. Drug Deliv. Rev.* 2, 31–54 (1988).
2. G. Gregoriadis. *Liposomes and Drug Carriers: Recent Trends and Progress*, John Wiley and Sons, New York, 1988.
3. T. M. Allen. Stealth liposomes: five years on. *J. Liposome Res.* 2, 289–305 (1992).
4. D. Papahadjopoulos, T. M. Allen, A. Gabizon, E. Mayhew, K. Matthey, S. K. Huang, K. D. Lee, M. C. Woodle, D. D. Lasic, C. Redemann and F. J. Martin. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. *Proc. Natl. Acad. Sci. USA.* 88, 11460–11464 (1991).
5. T. M. Allen and A. Chonn. Large unilamellar liposomes with low uptake into the reticuloendothelial system. *FEBS Lett.* 223, 42–46 (1987).
6. A. Gabizon and D. Papahadjopoulos. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. *Proc. Natl. Acad. Sci. USA.* 85, 6949–6953 (1988).
7. A. Mori, A. L. Klibnov, V. P. Torchilin and L. Huang. Influence of the steric barrier activity of amphipathic poly(ethylene glycol) and ganglioside GM₁ on the circulation time of liposomes and on the target binding of immunoliposomes *in vivo*. *FEBS Lett.* 284, 263–266 (1991).
8. T. M. Allen, C. Hansen, F. Martin, C. Redemann and A. Yauyoung. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives *in vivo*. *Biochim. Biophys. Acta.* 1066, 29–36 (1991).

Table II. Effect of Serum on Liposome Uptake by the Liver in a Perfusion System^a

Treatment	%Uptake ^b
PC/Chol/GM ₁ (10:5:1)	
Saline	4.6 ± 0.2
Rat serum	10.0 ± 0.4
Mouse serum	5.0 ± 0.9
Preheated rat serum (56°C, 30 min)	3.4 ± 0.6
PC/Chol (10:5)	
Saline	2.2 ± 0.1
Rat serum	2.1 ± 0.1

^a Liposomes (1 μmole total lipid) were preincubated with saline, normal or pretreated serum (33% in saline) for 10 min at 37°C. The mixture was then perfused through the liver as described under Materials and Methods.

^b The total liver uptake was as % of total perfused liposomes. Data are presented as mean ± S.D. (n = 2–4).

9. J. Senior, C. Delgado, D. Fisher, C. Tilock and G. Gregoriadis. Influence of surface hydrophilicity of liposomes on their interaction with plasma protein and clearance from the circulation: studies with poly(ethylene glycol)-coated vesicles. *Biochim. Biophys. Acta.* 1062, 77–82 (1991).
10. D. Liu, A. Mori and L. Huang. Role of liposome size and RES blockade in controlling biodistribution and tumor uptake of GM₁-containing liposomes. *Biochim. Biophys. Acta.* 1104, 95–101 (1992).
11. F. Roerdink, N. M. Wassef, E. C. Richardson and C. R. Alving. Effects of negatively charged lipids on phagocytosis of liposomes opsonized by complement. *Biochim. Biophys. Acta.* 734, 33–39 (1983).
12. J. T. P. Derksen, H. W. M. Morselt, D. Kalicharan, C. E. Hulstaert, and G. L. Scherphof. Interaction of immunoglobulin-coupled liposomes with rat liver macrophages *in vitro*. *Exp. Cell Res.* 168, 105–115 (1987).
13. M. J. Hsu and R. L. Juliano. Interactions of liposomes with the reticuloendothelial system. II: Nonspecific and receptor mediated uptake of liposomes by mouse peritoneal macrophages. *Biochim. Biophys. Acta.* 720, 411–419 (1982).
14. A. Chonn, S. C. Semple and P. R. Cullis. Association of blood proteins with large unilamellar liposomes *in vivo*: relation to circulation lifetime. *J. Biol. Chem.* 267, 18759–18765 (1992).
15. T. M. Allen, G. A. Austin, A. Chonn, L. Lin, and K. C. Lee. Uptake of liposomes by cultured mouse bone marrow macrophages: influence of liposome composition and size. *Biochim. Biophys. Acta.* 1062, 56–64 (1991).
16. S. M. Moghimi and H. M. Patel. Serum opsonins and phagocytosis of saturated and unsaturated phospholipid liposomes. *Biochim. Biophys. Acta.* 984, 384–387 (1989).
17. F. Ulrich and F. M. Meier. Inhibition of phagocytosis effects of normal rabbit serum on *E. coli* uptake by rabbit alveolar macrophages. *J. Reticuloendothel. Soc.* 14, 8–17 (1973).
18. M. S. Wu, J. C. Robbins, R. L. Bugianesi, M. M. Ponpipom and T. Y. Shen. Modified *in vivo* behavior of liposomes containing synthetic glycolipids. *Biochim. Biophys. Acta.* 674, 19–26 (1981).
19. T. Sjostrand. Circulation. In W. F. Hamilton (eds.) *Handbook of Physiology*, American Physiological Society, Washington, D.C., 1962, Vol. 1, pp. 51–62.
20. T. M. Allen and C. Hansen. Pharmacokinetics of stealth versus conventional liposomes: effect of dose. *Biochim. Biophys. Acta.* 1068, 133–141 (1991).
21. T. M. Allen, R. A. Schlegel and P. Williamson Phosphatidylserine as a determinant of reticuloendothelial recognition of liposome models of the erythrocyte surface. *Proc. Natl. Acad. Sci. USA* 85, 8067–8071 (1988).
22. C. R. Alving and L. R. Richard. In M. Ostro (ed.) *Liposomes from Biophysics to Therapeutics*. Marcel Dekker, New York, 1983, pp. 209–287.
23. H. C. Loughrey, M. B. Bally, L. W. Reinish and P. R. Cullis. The binding of phosphatidylglycerol liposomes to rat platelet is mediated by complement. *Thromb. Haemostasis* 64, 172–179 (1990).
24. A. Chonn, P. R. Cullis, and D. V. Devine. The role of surface charge in the activation of the classical and alternative pathways of complement by liposomes. *J. Immunology* 146, 4234–4241 (1991).
25. C. R. Alving and N. M. Wassef. Complement-dependent phagocytosis of liposomes by macrophages: suppressive effects of “stealth” lipids. *J. Liposome Res.* 2, 383–395 (1992).